Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma SA
Age
4–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female children, adolescents and adults having completed the final visit of a previous study with levetiracetam (LEV)
Subjects who were/are suffering from primary generalized (type II) epileptic seizures
Subjects for whom the Investigator believes a reasonable benefit (efficacy or tolerability) from the long-term administration of LEV may be expected
You may not be if
Known clinically significant acute or chronic illness, for example: cardiac, renal or hepatic dysfunction, etc., which may impair reliable participation in the trial or necessitate the use of medication not allowed by protocol
Concomitant use of any drug with possible central nervous system effects unless at a stable dose
Concomitant use of any drug (other than hormonal treatment and the subject's normal anti-epileptic drugs (AEDs) that may influence the metabolism of the concomitant AED(s), except if the dose has been stable before entry in the study for sufficient length of time
Clareo Health | Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
